4SC AG-Product Pipeline Review-2015

4SC AG-Product Pipeline Review-2015

  • Products Id :- GMDHC07258CDB
  • |
  • Pages: 71
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

4SC AG-Product Pipeline Review-2015


Global Markets Direct's, '4SC AG-Product Pipeline Review-2015', provides an overview of the 4SC AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of 4SC AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of 4SC AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of 4SC AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the 4SC AG's pipeline products

Reasons To Buy

Evaluate 4SC AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of 4SC AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the 4SC AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of 4SC AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of 4SC AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of 4SC AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

4SC AG Snapshot 7

4SC AG Overview 7

Key Information 7

Key Facts 7

4SC AG-Research and Development Overview 8

Key Therapeutic Areas 8

4SC AG-Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products-Monotherapy 13

Pipeline Products-Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Pipeline Products-Out-Licensed Products 16

Out-Licensed Products/Combination Treatment Modalities 17

4SC AG-Pipeline Products Glance 18

4SC AG-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

4SC AG-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

4SC AG-Drug Profiles 22

resminostat 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

vidofludimus 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

4SC-202 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

4SC-205 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

4SC-X09 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

CR-2408 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule for Malaria 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecule to Block Kv1.3 for Autoimmune Disorders 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecule to Inhibit Cytokine for Psoriasis 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Agonize TLR 7 for Cancer 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules to Agonize TLR 8 for Cancer 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

SC-92366 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecule to Inhibit GLI-1 for Cancer 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecules for Cancer 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules for Neurological Disorders 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules to Antagonize H4 for Autoimmune and Inflammatory Diseases 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Inhibit Bromodomain for Cancer 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecules to Inhibit Casein Kinase 1 for Cancer 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Small Molecules to Inhibit MSK1 for Autoimmune Diseases and Cancer 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Small Molecules to Inhibit MSK2 for Autoimmune Diseases and Cancer 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Small Molecules to Inhibit PAD4 for Oncology 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

4SC AG-Pipeline Analysis 53

4SC AG-Pipeline Products by Target 53

4SC AG-Pipeline Products by Route of Administration 55

4SC AG-Pipeline Products by Molecule Type 56

4SC AG-Pipeline Products by Mechanism of Action 57

4SC AG-Recent Pipeline Updates 59

4SC AG-Dormant Projects 66

4SC AG-Discontinued Pipeline Products 67

Discontinued Pipeline Product Profiles 67

4SC-203 67

4SC-207 67

4SC AG-Company Statement 68

4SC AG-Locations And Subsidiaries 69

Head Office 69

Other Locations & Subsidiaries 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

4SC AG, Key Information 7

4SC AG, Key Facts 7

4SC AG-Pipeline by Indication, 2015 9

4SC AG-Pipeline by Stage of Development, 2015 12

4SC AG-Monotherapy Products in Pipeline, 2015 13

4SC AG-Partnered Products in Pipeline, 2015 14

4SC AG-Partnered Products/ Combination Treatment Modalities, 2015 15

4SC AG-Out-Licensed Products in Pipeline, 2015 16

4SC AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 17

4SC AG-Phase II, 2015 18

4SC AG-Phase I, 2015 19

4SC AG-Preclinical, 2015 20

4SC AG-Discovery, 2015 21

4SC AG-Pipeline by Target, 2015 54

4SC AG-Pipeline by Route of Administration, 2015 55

4SC AG-Pipeline by Molecule Type, 2015 56

4SC AG-Pipeline Products by Mechanism of Action, 2015 58

4SC AG-Recent Pipeline Updates, 2015 59

4SC AG-Dormant Developmental Projects,2015 66

4SC AG-Discontinued Pipeline Products, 2015 67

4SC AG, Subsidiaries 69

List of Figures

4SC AG-Pipeline by Top 10 Indication, 2015 9

4SC AG-Pipeline by Stage of Development, 2015 12

4SC AG-Monotherapy Products in Pipeline, 2015 13

4SC AG-Partnered Products in Pipeline, 2015 14

4SC AG-Pipeline by Top 10 Target, 2015 53

4SC AG-Pipeline by Top 10 Route of Administration, 2015 55

4SC AG-Pipeline by Top 10 Molecule Type, 2015 56

4SC AG-Pipeline Products by Top 10 Mechanism of Action, 2015 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of 4SC AG; 4SC AG - Key Therapeutics; 4SC AG - Pipeline Overview and Promising Molecules; 4SC AG - News; 4SC AG - Latest Updates; 4SC AG - Pipeline; 4SC AG - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com